| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Ihre wichtigsten Termine: Heute im Fokus: Bertelsmann, Medtronic, Biontech, Rheinmetall & Imperial Brands | 1.403 | wallstreetONLINE | © Foto: Deutsche Börse AGGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:15... ► Artikel lesen | |
| Di | Morning Market Movers: Olema Pharmaceuticals, LifeMD, Alpha Technology Group, Intellinetics See Big Swings | 317 | AFX News | HELSINKI (dpa-AFX) - At 8:10 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| Di | Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc | 294 | Dow Jones News | DJ Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc
Zürcher Kantonalbank (AVDL)
Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc
18-Nov-2025 / 17:52 CET/CEST
=----------------------------------------------------------------------------------------------------------------------... ► Artikel lesen | |
| Di | Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc -2- | 280 | Dow Jones News | DJ Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc
Zürcher Kantonalbank (AVDL)
Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc
18-Nov-2025 / 17:52 CET/CEST
=----------------------------------------------------------------------------------------------------------------------... ► Artikel lesen | |
| Di | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference | 255 | PR Newswire | DUBLIN, Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company... ► Artikel lesen | |
| Di | XFRA HDP1: WIEDERAUFNAHME/RESUMPTION | 250 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| Di | Insmed Incorporated: European Commission Approves BRINSUPRI (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union | 239 | PR Newswire | - Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damagei -
- BRINSUPRI Is a First-in-Disease, First-in-Class DPP1... ► Artikel lesen | |
| Di | Viatris: Collaborating to Address Antimicrobial Resistance | 229 | ACCESS Newswire | NORTHAMPTON, MA / ACCESS Newswire / November 18, 2025 / Viatris takes a multi-pronged approach to actively engage in addressing AMR, both by providing access through our portfolio of more than 90 antimicrobials... ► Artikel lesen | |
| Di | Moderna, Inc.: Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025 | 228 | ACCESS Newswire | CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:Piper Sandler's 37th Annual... ► Artikel lesen | |
| Di | Zymeworks Inc.: Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer | 225 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, Nov. 18, 2025(Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics... ► Artikel lesen | |
| Di | Zymeworks Inc.: Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets | 224 | GlobeNewswire (Europe) | Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholdersStrategic initiative follows positive topline results from pivotal... ► Artikel lesen | |
| Di | Genmab A/S: Genmab Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma | 209 | Business Wire | Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line setting... ► Artikel lesen | |
| Di | Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc | 164 | Dow Jones News | DJ Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
The Vanguard Group, Inc. (IRSH)
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
18-Nov-2025 / 14:30 GMT/BST
... ► Artikel lesen | |
| Di | XFRA HDP1: AUSSETZUNG/SUSPENSION | 147 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILARROWHEAD PHARMAC.... ► Artikel lesen | |
| 04:06 | Genmab Announces Pricing Of Private Offering Of Senior Secured Notes And Senior Unsecured Notes | 121 | AFX News | WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) announced that the company and its wholly owned subsidiary Genmab Finance LLC have priced their offering of $1.5 billion of 6.250% senior secured notes... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| VIATRIS | 9,248 | 0,41 | +4,43 % | 0,12 | 24.11.2025 | |
| AMGEN | 296,60 | 8,21 | +2,77 % | 2,38 | 21.11.2025 | |
| GILEAD SCIENCES | 109,90 | 2,71 | +2,47 % | 0,79 | 15.12.2025 | |
| ROYALTY PHARMA | 34,010 | 0,76 | +2,23 % | 0,22 | 14.11.2025 | |
| REGENERON PHARMACEUTICALS | 626,20 | 3,04 | +0,49 % | 0,88 | 20.11.2025 | |
| IONIS PHARMACEUTICALS | 63,64 | 0,00 | 0,00 % | |||
| BIOGEN | 145,90 | 0,00 | 0,00 % | |||
| VERA THERAPEUTICS | 28,880 | 0,00 | 0,00 % | |||
| LENZ THERAPEUTICS | 27,230 | 0,00 | 0,00 % |
| Aktien WKN | Akt. Kurs Vortag | +/- % | Zeit | ||
|---|---|---|---|---|---|
| 10X GENOMICS INC A2PPQJ Tradegate | 13,420 13,540 | -0,015 -0,11 % | 18.11. | ||
| 4D MOLECULAR THERAPEUTICS INC A2PS5P NASDAQ | 10,060 10,955 | -0,895 -8,17 % | 18.11. | ||
| ABCELLERA BIOLOGICS INC A2QKXS Tradegate | 3,177 3,103 | +0,012 +0,38 % | 18.11. | ||
| ABSCI CORPORATION A3CVW3 NASDAQ | 2,835 2,865 | -0,025 -0,87 % | 18.11. | ||
| AC IMMUNE SA A2AR5F Tradegate | 2,640 2,670 | +0,010 +0,38 % | 18.11. | ||
| ACADIA PHARMACEUTICALS INC 603035 Tradegate | 20,570 20,720 | +0,010 +0,05 % | 18.11. | ||
| ACRIVON THERAPEUTICS INC A3DXE7 NASDAQ | 2,410 2,365 | +0,045 +1,90 % | 18.11. | ||
| ADAPTIVE BIOTECHNOLOGIES CORPORATION A2PLR5 Tradegate | 11,475 11,845 | -0,405 -3,41 % | 18.11. | ||
| ADMA BIOLOGICS INC A12FAG NASDAQ | 15,685 15,415 | +0,270 +1,75 % | 18.11. | ||
| AGIOS PHARMACEUTICALS INC A1W2RM Tradegate | 38,800 39,000 | -0,600 -1,52 % | 18.11. |